FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

FBLG FibroBiologics

盘前交易 02-11 08:57:06 EST

0.2672

+0.0157

+6.24%

盘前0.2672

+0.00000.00%

08:36 EST

最高0.2842	最低0.2495	成交量95.96万
今开0.2495	昨收0.2515	日振幅13.82%
总市值1,777万	流通市值1,511万	总股本6,652万
成交额26.06万	换手率1.70%	流通股本5,656万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"FBLG","market":"US","secType":"STK","nameCN":"FibroBiologics","latestPrice":0.2672,"timestamp":1770757200000,"preClose":0.2515,"halted":0,"volume":959597,"hourTrading":{"tag":"盘前","latestPrice":0.2672,"preClose":0.2672,"latestTime":"08:36 EST","volume":3918,"amount":1051.41869046,"timestamp":1770816993078,"change":0,"changeRate":0,"amplitude":0.104416},"delay":0,"changeRate":0.06242544731610335,"floatShares":56556500,"shares":66519700,"eps":-0.484982,"marketStatus":"盘前交易","change":0.0157,"latestTime":"02-11 08:57:06 EST","open":0.24945,"high":0.2842,"low":0.24945,"amount":260630.15328472003,"amplitude":0.138171,"askPrice":0.2672,"askSize":53,"bidPrice":0.2444,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.484982,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770820200000},"marketStatusCode":1,"adr":0,"listingDate":1706677200000,"exchange":"NASDAQ","adjPreClose":0.2672,"preHourTrading":{"tag":"盘前","latestPrice":0.2672,"preClose":0.2672,"latestTime":"08:36 EST","volume":3918,"amount":1051.41869046,"timestamp":1770816993078,"change":0,"changeRate":0,"amplitude":0.104416},"postHourTrading":{"tag":"盘后","latestPrice":0.2625,"preClose":0.2672,"latestTime":"18:36 EST","volume":105237,"amount":29261.847738,"timestamp":1770766572363,"change":-0.0047,"changeRate":-0.01759,"amplitude":0.15494},"volumeRatio":0.552392229627094},"requestUrl":"/m/hq/s/FBLG/tweets","defaultTab":"tweets","newsList":[{"id":"2601814747","title":"Fibrobiologics, Inc.盘中异动 快速上涨5.05%报0.256美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601814747","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601814747?lang=zh_cn&edition=full","pubTime":"2026-01-07 00:32","pubTimestamp":1767717138,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日00时32分，Fibrobiologics, Inc.股票出现波动，股价快速上涨5.05%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107003219953c190e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107003219953c190e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1185969009","title":"FibroBiologics公布成纤维细胞球源性软骨细胞球疗法治疗退行性椎间盘疾病的积极临床前结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1185969009","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185969009?lang=zh_cn&edition=full","pubTime":"2026-01-05 21:30","pubTimestamp":1767619821,"startTime":"0","endTime":"0","summary":"FibroBiologics（股票代码：FBLG）近日宣布，其针对退行性椎间盘疾病研发的成纤维细胞球源性软骨细胞（Fsdc）球疗法在临床前研究中取得积极成果。该疗法展现出了良好的治疗潜力，为后续的临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1126005925","title":"FibroBiologics向美国FDA提交新药临床试验申请 推进Cyps317治疗银屑病临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1126005925","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126005925?lang=zh_cn&edition=full","pubTime":"2025-12-31 21:31","pubTimestamp":1767187874,"startTime":"0","endTime":"0","summary":"FibroBiologics已正式向美国食品药品监督管理局提交新药临床试验申请，旨在加速其候选药物Cyps317在银屑病患者中的临床开发进程。这一重要监管步骤标志着该疗法向临床应用迈出了关键一步，为后续临床试验的开展铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2594594244","title":"Fibrobiologics, Inc.盘中异动 大幅上涨5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594594244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594594244?lang=zh_cn&edition=full","pubTime":"2025-12-27 05:00","pubTimestamp":1766782810,"startTime":"0","endTime":"0","summary":"北京时间2025年12月27日05时00分，Fibrobiologics, Inc.股票出现波动，股价大幅上涨5.55%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227050011a47cdae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227050011a47cdae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1170596843","title":"FibroBiologics宣布以市场价格进行170万美元的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1170596843","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170596843?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:04","pubTimestamp":1765803862,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布以市场价格进行170万美元的注册直接发行，符合纳斯达克的相关规则。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"1190833209","title":"FibroBiologics Inc - 全部清偿对Ya Ii Pn, Ltd. 发行的可转换票据的未偿还金额","url":"https://stock-news.laohu8.com/highlight/detail?id=1190833209","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190833209?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:33","pubTimestamp":1764164015,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc - 全部清偿对Ya Ii Pn, Ltd. 发行的可转换票据的未偿还金额。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1111063136","title":"FibroBiologics完成150万美元的直接注册发行，定价符合纳斯达克规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1111063136","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111063136?lang=zh_cn&edition=full","pubTime":"2025-11-26 05:05","pubTimestamp":1764104737,"startTime":"0","endTime":"0","summary":"FibroBiologics完成150万美元的直接注册发行，定价符合纳斯达克规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586024344","title":"Fibrobiologics, Inc.盘中异动 股价大涨5.31%报0.274美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586024344","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586024344?lang=zh_cn&edition=full","pubTime":"2025-11-26 01:01","pubTimestamp":1764090067,"startTime":"0","endTime":"0","summary":"北京时间2025年11月26日01时01分，Fibrobiologics, Inc.股票出现波动，股价急速上涨5.31%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.34%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126010107977efa9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126010107977efa9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2586410161","title":"Fibrobiologics, Inc.股价重挫23.56% 市值跌315.07万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586410161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586410161?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:31","pubTimestamp":1763994713,"startTime":"0","endTime":"0","summary":"北京时间2025年11月24日22时31分，Fibrobiologics, Inc.股票出现波动，股价急速跳水23.56%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.35%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223153a4b752f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124223153a4b752f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"1121264409","title":"FibroBiologics宣布按照纳斯达克规则以市场价格发行150万美元的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1121264409","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121264409?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:02","pubTimestamp":1763992935,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布按照纳斯达克规则以市场价格发行150万美元的注册直接发行","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"1189216448","title":"FibroBiologics获得Hrec批准，启动Cywc628治疗难治性糖尿病足溃疡的1/2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1189216448","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189216448?lang=zh_cn&edition=full","pubTime":"2025-11-20 21:02","pubTimestamp":1763643738,"startTime":"0","endTime":"0","summary":"FibroBiologics获得Hrec批准，启动Cywc628治疗难治性糖尿病足溃疡的1/2期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1124789526","title":"FibroBiologics宣布以纳斯达克规则进行的400万美元注册直接发售成交","url":"https://stock-news.laohu8.com/highlight/detail?id=1124789526","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124789526?lang=zh_cn&edition=full","pubTime":"2025-11-20 08:05","pubTimestamp":1763597111,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布以市场价格完成400万美元的注册直接发售，该发售遵循纳斯达克规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1150886788","title":"FibroBiologics公布400万美元注册直接发行的定价，符合纳斯达克市场规则","url":"https://stock-news.laohu8.com/highlight/detail?id=1150886788","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150886788?lang=zh_cn&edition=full","pubTime":"2025-11-19 21:39","pubTimestamp":1763559541,"startTime":"0","endTime":"0","summary":"FibroBiologics公布400万美元注册直接发行的定价，符合纳斯达克市场规则","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2581854970","title":"Fibrobiologics, Inc.盘中异动 早盘大幅拉升7.80%报0.353美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581854970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581854970?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:32","pubTimestamp":1762353155,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日22时32分，Fibrobiologics, Inc.股票出现波动，股价大幅上涨7.80%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.47%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105223235a48adf60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105223235a48adf60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"1153706268","title":"FibroBiologics Inc：正准备提交Cyps317治疗银屑病的临床试验新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1153706268","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153706268?lang=zh_cn&edition=full","pubTime":"2025-11-01 04:34","pubTimestamp":1761942866,"startTime":"0","endTime":"0","summary":"FibroBiologics Inc：正准备提交Cyps317治疗银屑病的临床试验新药申请","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2575242576","title":"Fibrobiologics, Inc.盘中异动 早盘股价大跌5.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575242576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575242576?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:05","pubTimestamp":1760450730,"startTime":"0","endTime":"0","summary":"北京时间2025年10月14日22时05分，Fibrobiologics, Inc.股票出现异动，股价急速下跌5.50%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014220530a6b9217f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014220530a6b9217f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"1179889476","title":"FibroBiologics宣布积极的IND申请进展更新，展示成纤维细胞球体在慢性复发性银屑病治疗中的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1179889476","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179889476?lang=zh_cn&edition=full","pubTime":"2025-09-11 20:31","pubTimestamp":1757593879,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布积极的IND申请进展更新，展示成纤维细胞球体在慢性复发性银屑病治疗中的潜力","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"1119399927","title":"FibroBiologics宣布骨髓类器官平台取得重大进展，助力开发癌症和免疫相关疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1119399927","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119399927?lang=zh_cn&edition=full","pubTime":"2025-09-10 20:31","pubTimestamp":1757507478,"startTime":"0","endTime":"0","summary":"FibroBiologics宣布骨髓类器官平台取得重大进展，助力开发癌症和免疫相关疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"gpt_icon":0},{"id":"2517943352","title":"Fibrobiologics, Inc.盘中异动 股价大涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517943352?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:35","pubTimestamp":1741185301,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时35分，Fibrobiologics, Inc.股票出现波动，股价快速上涨5.31%。Fibrobiologics, Inc.股票所在的生物技术行业中，整体涨幅为0.58%。Fibrobiologics, Inc.公司简介：FibroBiologics Inc 是一家临床阶段细胞治疗公司，专注于开发和商业化基于成纤维细胞的治疗方法，用于治疗患有严重未满足医疗需求的慢性疾病的患者，包括退行性椎间盘疾病、多发性硬化症、伤口愈合和某些癌症以及潜在的延长生命应用，包括胸腺和脾脏退化逆转。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501a260c8a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501a260c8a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["FBLG","BK4139"],"gpt_icon":0},{"id":"2517909607","title":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517909607","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517909607?lang=zh_cn&edition=full","pubTime":"2025-03-05 02:11","pubTimestamp":1741111897,"startTime":"0","endTime":"0","summary":"D. Boral Capital：维持FibroBiologics(FBLG.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05021148524222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["FBLG"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fibrobiologics.com","stockEarnings":[{"period":"1week","weight":-0.0364},{"period":"1month","weight":-0.2095},{"period":"3month","weight":-0.1856},{"period":"6month","weight":-0.5456},{"period":"1year","weight":-0.849},{"period":"ytd","weight":0.1881}],"compareEarnings":[{"period":"1week","weight":0.0038},{"period":"1month","weight":-0.0028},{"period":"3month","weight":0.0128},{"period":"6month","weight":0.0731},{"period":"1year","weight":0.1443},{"period":"ytd","weight":0.015}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"FibroBiologics, Inc.最初于2021年4月8日根据德克萨斯州法律成立为有限责任公司，然后于2021年12月14日转变为特拉华州公司。FibroBiologics是一家早期细胞治疗公司，总部位于德克萨斯州休斯顿，开发利用成纤维细胞治疗慢性疾病的创新疗法。该公司的主要重点是启动和推进与成纤维细胞治疗退行性椎间盘疾病、多发性硬化症、癌症、伤口愈合和其他疾病相关的临床前研究和临床阶段FDA试验。","exchange":"NASDAQ","name":"FibroBiologics","nameEN":"FibroBiologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"FibroBiologics,FBLG,FibroBiologics股票,FibroBiologics股票老虎,FibroBiologics股票老虎国际,FibroBiologics行情,FibroBiologics股票行情,FibroBiologics股价,FibroBiologics股市,FibroBiologics股票价格,FibroBiologics股票交易,FibroBiologics股票购买,FibroBiologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"FibroBiologics(FBLG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供FibroBiologics(FBLG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}